MicroRNA 214 Inhibits Adipocyte Enhancer-binding Protein 1 Activity and Increases the Sensitivity of Chemotherapy in Colorectal Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jan 19

PMID 30655737

Citations 7

Authors

Shouchao Li

Chengren Li

Zhiming Fang

Affiliations

Soon will be listed here.

Abstract

The present study aimed to analyze adipocyte enhancer-binding protein 1 (AEBP1) expression in colorectal cancer (CRC), with a focus on its possible molecular mechanisms, in order to provide novel insight into the clinical treatment of CRC. Immunohistochemistry (IHC) was used to detect AEBP1 expression in 62 CRC tissues. Kaplan-Meier survival curves were used to analyze AEBP1 expression and the postoperative disease-free survival (DFS) and overall survival (OS) rates of CRC patients. HT-29 cells were treated with oxaliplatin to detect cell proliferation and apoptosis following a Cell Counting kit-8. Through bioinformatics prediction, microRNA 214 (miR214) was identified as an upstream microRNA of AEBP1 that regulates its expression. IHC revealed that the expression of AEBP1 in CRC tissues was significantly higher than that in adjacent healthy tissues, and that it is associated with Tumor-Node-Metastasis stage, recurrence and metastasis. The DFS and OS rates of patients with a low AEBP1 expression were significantly higher than those in patients with a high expression (P<0.05). Following depletion of AEBP1 and treatment with oxaliplatin, the HT-29 cell proliferation was lower than that of the blank control and the negative control groups. However, the cell apoptosis rate was higher than that of the control group at 72 h (P<0.05). Bioinformatics prediction revealed that miR-214 is negatively associated with AEBP1 expression, and co-transfection and luciferase report gene tests revealed that AEBP1 is a target gene of miR-214. Therefore, AEBP1 may become a novel treatment for CRC patients with chemoresistance and may act through the upstream miR-214 to participate in the progression of a tumor.

Citing Articles

ACLP Activates Cancer-Associated Fibroblasts and Inhibits CD8+ T-Cell Infiltration in Oral Squamous Cell Carcinoma.

Sekiguchi S, Yorozu A, Okazaki F, Niinuma T, Takasawa A, Yamamoto E Cancers (Basel). 2023; 15(17).

PMID: 37686580 PMC: 10486706. DOI: 10.3390/cancers15174303.

The role of non-coding RNAs in chemotherapy for gastrointestinal cancers.

Dashti F, Mirazimi S, Rabiei N, Fathazam R, Rabiei N, Piroozmand H Mol Ther Nucleic Acids. 2021; 26:892-926.

PMID: 34760336 PMC: 8551789. DOI: 10.1016/j.omtn.2021.10.004.

AEBP1 is a Novel Oncogene: Mechanisms of Action and Signaling Pathways.

Majdalawieh A, Massri M, Ro H J Oncol. 2020; 2020:8097872.

PMID: 32565808 PMC: 7273425. DOI: 10.1155/2020/8097872.

Mechanisms of aortic carboxypeptidase-like protein secretion and identification of an intracellularly retained variant associated with Ehlers-Danlos syndrome.

Vishwanath N, Monis W, Hoffmann G, Ramachandran B, DiGiacomo V, Wong J J Biol Chem. 2020; 295(28):9725-9735.

PMID: 32482891 PMC: 7363150. DOI: 10.1074/jbc.RA120.013902.

Down-regulation of lncRNA DNAJC3-AS1 inhibits colon cancer via regulating miR-214-3p/LIVIN axis.

Han B, Ge Y, Cui J, Liu B Bioengineered. 2020; 11(1):524-535.

PMID: 32352854 PMC: 7202691. DOI: 10.1080/21655979.2020.1757224.

References

Mishra P, Humeniuk R, Mishra P, Longo-Sorbello G, Banerjee D, Bertino J . A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc Natl Acad Sci U S A. 2007; 104(33):13513-8. PMC: 1948927. DOI: 10.1073/pnas.0706217104. View

Yamashita S, Takahashi S, McDonell N, Watanabe N, Niwa T, Hosoya K . Methylation silencing of transforming growth factor-beta receptor type II in rat prostate cancers. Cancer Res. 2008; 68(7):2112-21. DOI: 10.1158/0008-5472.CAN-07-5282. View

Yang Z, Chen S, Luan X, Li Y, Liu M, Li X . MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009; 61(11):1075-82. DOI: 10.1002/iub.252. View

Majdalawieh A, Ro H . Regulation of IkappaBalpha function and NF-kappaB signaling: AEBP1 is a novel proinflammatory mediator in macrophages. Mediators Inflamm. 2010; 2010:823821. PMC: 2855089. DOI: 10.1155/2010/823821. View

Majdalawieh A, Ro H . PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1. Nucl Recept Signal. 2010; 8:e004. PMC: 2858268. DOI: 10.1621/nrs.08004. View

Valeri N, Gasparini P, Braconi C, Paone A, Lovat F, Fabbri M . MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A. 2010; 107(49):21098-103. PMC: 3000294. DOI: 10.1073/pnas.1015541107. View

Qiang R, Wang F, Shi L, Liu M, Chen S, Wan H . Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int J Biochem Cell Biol. 2011; 43(4):632-41. DOI: 10.1016/j.biocel.2011.01.002. View

Bogachev O, Majdalawieh A, Pan X, Zhang L, Ro H . Adipocyte enhancer-binding protein 1 (AEBP1) (a novel macrophage proinflammatory mediator) overexpression promotes and ablation attenuates atherosclerosis in ApoE (-/-) and LDLR (-/-) mice. Mol Med. 2011; 17(9-10):1056-64. PMC: 3188858. DOI: 10.2119/molmed.2011.00141. View

Hu H, Krasinskas A, Willis J . Perspectives on current tumor-node-metastasis (TNM) staging of cancers of the colon and rectum. Semin Oncol. 2011; 38(4):500-10. DOI: 10.1053/j.seminoncol.2011.05.004. View

10.

Ladha J, Sinha S, Bhat V, Donakonda S, Rao S . Identification of genomic targets of transcription factor AEBP1 and its role in survival of glioma cells. Mol Cancer Res. 2012; 10(8):1039-51. DOI: 10.1158/1541-7786.MCR-11-0488. View

11.

Holloway R, Bogachev O, Bharadwaj A, McCluskey G, Majdalawieh A, Zhang L . Stromal adipocyte enhancer-binding protein (AEBP1) promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog signaling. J Biol Chem. 2012; 287(46):39171-81. PMC: 3493957. DOI: 10.1074/jbc.M112.404293. View

12.

Ku G, Tan I, Yau T, Boku N, Laohavinij S, Cheng A . Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncol. 2012; 13(11):e470-81. DOI: 10.1016/S1470-2045(12)70424-2. View

13.

van de Velde C, Aristei C, Boelens P, Beets-Tan R, Blomqvist L, Borras J . EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer. 2013; 49(13):2784-90. DOI: 10.1016/j.ejca.2013.04.032. View

14.

Fang Y, Shen H, Li H, Cao Y, Qin R, Long L . miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochim Biophys Sin (Shanghai). 2013; 45(11):963-72. DOI: 10.1093/abbs/gmt106. View

15.

Hu W, Jin L, Jiang C, Long G, Scolyer R, Wu Q . AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death Dis. 2013; 4:e914. PMC: 3847319. DOI: 10.1038/cddis.2013.441. View

16.

Muthalagu N, Junttila M, Wiese K, Wolf E, Morton J, Bauer B . BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep. 2014; 8(5):1347-53. PMC: 4231288. DOI: 10.1016/j.celrep.2014.07.057. View

17.

Fukushima K, Tsuchiya K, Kano Y, Horita N, Hibiya S, Hayashi R . Atonal homolog 1 protein stabilized by tumor necrosis factor α induces high malignant potential in colon cancer cell line. Cancer Sci. 2015; 106(8):1000-7. PMC: 4556389. DOI: 10.1111/cas.12703. View

18.

Sumpio C, Knobf M, Jeon S . Treatment complexity: a description of chemotherapy and supportive care treatment visits in patients with advanced-stage cancer diagnoses. Support Care Cancer. 2015; 24(1):285-293. DOI: 10.1007/s00520-015-2775-9. View

19.

Andersen H, Bertelsen C, Henriksen R, Campos A, Kristensen B, Ingeholm P . The pathological phenotype of colon cancer with microsatellite instability. Dan Med J. 2016; 63(2). View

20.

Young J, Mongoue-Tchokote S, Wieghard N, Mori M, Vaccaro G, Sheppard B . Treatment and Survival of Small-bowel Adenocarcinoma in the United States: A Comparison With Colon Cancer. Dis Colon Rectum. 2016; 59(4):306-15. DOI: 10.1097/DCR.0000000000000562. View